The privacy regulator was alerted to hundreds of data breaches in the first half of 2024, the highest number in three and a half years, a new report shows.
Expect more cybersecurity class actions following the introduction of a new statutory tort for serious invasions of privacy, experts on both sides of the bar table told Lawyerly.
Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.
A Sydney law firm has filed a class action accusing private equity-owned medical device maker Exactech of supplying faulty joint implants that were subject to deterioration due to a packaging defect, caused serious medical complications in patients.
A class action on behalf of 700 patients alleging assisted reproduction provider Monash IVF destroyed potentially viable embryos in a faulty genetic screening program has settled for $56 million.
A GlaxoSmithKline unit has defeated Nova Pharmaceuticals’ bid to trade mark ‘Novadart’ for a generic version of the British company’s market-leading drug prostate drug ‘Avodart’, with a delegate finding the mark would cause consumer confusion.
US-based Dana-Farber Cancer Institute has succeeded in patenting a patient-specific method for developing cancer vaccines using genome sequencing.
Monash IVF and a host of IVF clinics have taken Insurance Australia Ltd to court over coverage ahead of mediation in a class action alleging the companies destroyed potentially viable embryos.
After leading the first in a series of class actions by thousands of junior doctors to victory at trial, the applicant in a landmark wage case against Peninsula Health has told a judge the penalty against the Victorian hospital operator must send a clear message.
A contradictor has argued against Monash IVF’s bid for orders allowing it to retain embryos as evidence in a class action, saying the Victorian Supreme Court has no power to make orders inconsistent with the company’s statutory obligation to store embryos for a maximum of five years.